An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Copenhagen

About this trial

Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is associated with several other chronic liver diseases like autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hereditary hemochromatosis and alpha-1-antitrypsin deficiency and may also develop secondary to other diseases like inflammatory bowel disease and chronic pancreatitis. Diagnosing chronic liver diseases can be challenging and treatment may be limited. In-depth phenotyping at a tissue level may generate insight into the underlying pathophysiology of diseases and furthermore identify common as well as specific diagnostic biomarkers and future treatment targets of the diseases. We therefore undertake a study that evaluates patients with chronic liver diseases associated with hepatic steatosis.

Eligibility criteria

Qualifiers

Adult patients/healthy control participants (age 18 or above) who can give their informed consent

non-alcoholic steatohepatitis

alcoholic steatohepatitis

autoimmune hepatitis

Disqualifiers

malignant diseases

viral hepatitis

human immunodeficiency virus

contraindications to liver biopsy

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

University of Copenhagen

Lead sponsor

Hvidovre University Hospital

Collaborator